Effects of aspirin on clot structure and fibrinolysis using a novel in vitro cellular system

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 5, 2009, Pages 712-717

  Ajjan, R A ^a   Standeven, K F ^a   Khanbhai, M ^a   Phoenix, F ^a   Gersh, K C ^b   Weisel, J W ^b   Kearney, M T ^a   Ariens R A S ^a   Grant, P J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acetylation; Aspirin; Fibrin polymerization; Fibrin structure; Fibrinogen; Fibrinolysis

Indexed keywords

ACETYLSALICYLIC ACID; FIBRIN; FIBRINOGEN; RECOMBINANT PROTEIN;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ARTICLE; BIOCHEMISTRY; BLOOD CLOTTING; CELL GROWTH; CELL LINE; CHO CELL; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG EFFICACY; EX VIVO STUDY; FIBER; FIBRIN CLOT; FIBRINOLYSIS; FLOW MEASUREMENT; HUMAN; IN VITRO STUDY; NONHUMAN; NORMAL HUMAN; PERMEABILITY; PRIORITY JOURNAL; RIGIDITY; SCANNING ELECTRON MICROSCOPY; THICKNESS; TREATMENT DURATION; TURBIDITY; ANIMAL; CRICETULUS; HAMSTER;

ANIMALS; ASPIRIN; BLOOD COAGULATION; CHO CELLS; CRICETINAE; CRICETULUS; FIBRINOGEN; FIBRINOLYSIS;

EID: 65549088060     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.183707     Document Type: Article

References (27)

1. Reaume KT, Regal RE, Dorsch MP. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use. Ann Pharmacother. 2008;42:550-557.
2. Undas A, Brummel-Ziedins KE, Mann KG. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood. 2007;109:2285-2292.
3. Ajjan RA, Grant PJ. Role of clotting factors and fibrin structure in predisposition to atherothrombotic disease. Expert Rev Cardiovasc Ther. 2005;3:1047-1059.
4. Collet JP, Park D, Lesty C, Soria J, Soria C, Montalescot G, Weisel JW. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol. 2000;20:1354-1361.
5. Fatah K, Silveira A, Tornvall P, Karpe F, Blomback M, Hamsten A. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost. 1996;76: 535-540.
6. Pinckard RN, Hawkins D, Farr RS. In vitro acetylation of plasma proteins, enzymes and DNA by aspirin. Nature. 1968;219:68-69.
7. He S, Blomback M, Yoo G, Sinha R, Henschen-Edman AH. Modified clotting properties of fibrinogen in the presence of acetylsalicylic acid in a purified system. Ann N Y Acad Sci. 2001;936:531-535.
8. Henschen-Edman AH. Fibrinogen non-inherited heterogeneity and its relationship to function in health and disease. Ann N Y Acad Sci. 2001; 936:580-593.
9. Fatah K, Beving H, Albage A, Ivert T, Blomback M. Acetylsalicylic acid may protect the patient by increasing fibrin gel porosity. Is withdrawing of treatment harmful to the patient? Eur Heart J. 1996; 17:1362-1366.
10. Williams S, Fatah K, Hjemdahl P, Blomback M. Better increase in fibrin gel porosity by low dose than intermediate dose acetylsalicylic acid. Eur Heart J. 1998;19:1666-1672.
11. Antovic A, Perneby C, Ekman GJ, Wallen HN, Hjemdahl P, Blomback M, He S. Marked increase of fibrin gel permeability with very low dose ASA treatment. Thromb Res. 2005;116:509-517.
12. Undas A, Sydor WJ, Brummel K, Musial J, Mann KG, Szczeklik A. Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism. Circulation. 2003;107:17-20.
13. Upchurch Jr GR, Ramdev N, Walsh MT, Loscalzo J. Prothrombotic consequences of the oxidation of fibrinogen and their inhibition by aspirin. J Thromb Thrombolysis. 1998;5:9-14.
14. Bjornsson TD, Schneider DE, Berger H Jr. Aspirin acetylates fibrinogen and enhances fibrinolysis. Fibrinolytic effect is independent of changes in plasminogen activator levels. J Pharmacol Exp Ther. 1989;250:154-161.
15. Ajjan R, Lim BC, Standeven KF, Harrand R, Dolling S, Phoenix F, Greaves R, Abou-Saleh RH, Connell S, Smith DA, Weisel JW, Grant PJ, Ariens RA. Common variation in the C-terminal region of the fibrinogen beta-chain: effects on fibrin structure, fibrinolysis and clot rigidity. Blood. 2008;111:643-650.
16. Cerletti C, Bonati M, del Maschio A, Galletti F, Dejana E, Tognoni G, de Gaetano G. Plasma levels of salicylate and aspirin in healthy volunteers: relevance to drug interaction on platelet function. J Lab Clin Med. 1984;103:869-877.
17. Benedek IH, Joshi AS, Pieniaszek HJ, King SY, Kornhauser DM. Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. J Clin Pharmacol. 1995;35: 1181-1186.
18. Schwertner HA, McGlasson D, Christopher M, Bush AC. Effects of different aspirin formulations on platelet aggregation times and on plasma salicylate concentrations. Thromb Res. 2006;118:529-534.
19. Takebe M, Soe G, Kohno I, Sugo T, Matsuda M. Calcium ion-dependent monoclonal antibody against human fibrinogen: preparation, characterization, and application to fibrinogen purification. Thromb Haemost. 1995;73:662-667.
20. Woodhead JL, Nagaswami C, Matsuda M, Arocha-Pinango CL, Weisel JW. The ultrastructure of fibrinogen Caracas II molecules, fibers, and clots. J Biol Chem. 1996;271:4946-4953.
21. Standeven KF, Ariens RA, Whitaker P, Ashcroft AE, Weisel JW, Grant PJ. The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation. Diabetes. 2002; 51:189-197.
22. Buchanan MR, Rischke JA, Hirsh J. Aspirin inhibits platelet function independent of the acetylation of cyclo-oxygenase. Thromb Res. 1982; 25:363-373.
23. Hanson SR, Harker LA, Bjornsson TD. Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition. J Clin Invest. 1985;75:1591-1599.
24. Blinc A, Planinsic G, Keber D, Jarh O, Lahajnar G, Zidansek A, Demsar F. Dependence of blood clot lysis on the mode of transport of urokinase into the clot-a magnetic resonance imaging study in vitro. Thromb Haemost. 1991;65:549-552.
25. Gabriel DA, Muga K, Boothroyd EM. The effect of fibrin structure on fibrinolysis. J Biol Chem. 1992;267:24259-24263.
26. Scrutton MC, Ross-Murphy SB, Bennett GM, Stirling Y, Meade TW. Changes in clot deformability-a possible explanation for the epidemiological association between plasma fibrinogen concentration and myocardial infarction. Blood Coagul Fibrinolysis. 1994;5: 719-723.
27. Collet JP, Allali Y, Lesty C, Tanguy ML, Silvain J, Ankri A, Blanchet B, Dumaine R, Gianetti J, Payot L, Weisel JW, Montalescot G. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol. 2006;26: 2567-2573.